Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
May 21, 2024

Teva and Alvotech launch SIMLANDI in US for arthritis

Teva and Alvotech have announced the US launch of SIMLANDI (adalimumab-ryvk) injection, as an interchangeable biosimilar to the reference product Humira to treat arthritis.

SIMLANDI is a biosimilar to Humira approved by the FDA for treating multiple inflammatory conditions. Credit: u_8wvjvqzkws from Pixabay.